Pevec D, Novinscak T, Brcic L, et al
Calcium channel blockers (CCBs) are divided into dihydropyridine and non-dihydropyridine classes
These codes are reported per vaccine/toxoid component
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy [9]
well-tolerated in mice, rats, rabbits, and dogs with no serious organ toxicity.[34][35] Clinical Safety : Mild local irritation possible at injection sites, but no systemic adverse effects reported in trials.[36][37] Potential Risks : Theoretical concerns include pro-angiogenic effects potentially promoting tumor growth, though no evidence supports this in studies.[38] Long-term human data is limited, so monitoring is advised